Reversible termination nucleotides and their applications in DNA synthesis sequencing and single-molecule sequencing
By using a novel reversible nucleotide with a thiazoline linker, the linker is rapidly cleaved under the action of a palladium catalyst, which solves the problems of insufficiently mild cleavage conditions and low efficiency in the prior art, and improves the read length and efficiency of DNA sequencing.
Patent Information
- Application Number
- CN202410228897.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-29
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-02-29
AI Technical Summary
Existing reversible nucleotide linker units are not cleaved under mild conditions in DNA sequencing, resulting in low cleavage efficiency, short read lengths, and reduced sequencing efficiency.
A novel reversible nucleotide based on thiazolidinyl linker unit is used to achieve clean and thorough breakage of DNA strand elongation by rapidly cleaving the linker unit under the action of palladium catalyst, thus avoiding side reactions.
Rapid and thorough ligation of linker units was achieved under mild conditions, improving read length and efficiency in DNA sequencing and reducing DNA damage.
Smart Images

Figure CN118084996B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering technology, and more specifically, to a reversible termination nucleotide and its application in DNA synthesis sequencing and single-molecule sequencing. Background Technology
[0002] DNA sequencing technology is one of the most important tools in modern biological research. Following the completion of the Human Genome Project, DNA sequencing technology has developed rapidly. DNA sequencing refers to the analysis of the base sequence of a specific DNA fragment, that is, the arrangement of adenine (A), thymine (T), cytosine (C), and guanine (G). Developing accurate, high-throughput, and low-cost DNA sequencing methods is of great significance for biological and medical sciences.
[0003] Sequencing by Synthesis (SBS) is a next-generation DNA sequencing technology. This method involves immobilizing a large number of template DNA fragments and hybridizing them to a fixed DNA sequencing template with universal DNA primers. The extension of four nucleotides along these primers is controlled. By detecting the extension reaction process or the extending nucleotides, high-throughput parallel detection of DNA sequence information is achieved.
[0004] In synthetic sequencing, the first step is to synthesize nucleotides with four different bases labeled with four different fluorescent markers for DNA chain elongation, known as reversible terminators. Early reversible terminators, besides requiring 3'-hydroxyl blocking, also required a cleavable linker unit to connect the nucleotides and the fluorescein to avoid affecting the elongation and recognition of the next reversible terminator. Then, before the next reversible terminator is incorporated, this linker unit is broken under mild conditions to continue DNA chain elongation, thereby reading the DNA base sequence. This linker unit has a significant impact on the read length and efficiency of synthetic sequencing; therefore, researchers have been working to develop new cleavable linker units to improve DNA sequencing efficiency. Currently reported linker units include disulfide compounds, azo compounds, ketal compounds, o-nitrobenzyl compounds, o-diol compounds, azide compounds, and allyl ester compounds. However, the synthesis of reversible terminators based on thiazolidinyl compounds has not been reported. This invention discovers that the cleavage conditions of the thiazolidinyl linker unit are mild and rapid, making it highly suitable as a cleavable linker unit for DNA sequencing.
[0005] Cleavable linker units have a significant impact on read length and efficiency in DNA sequencing. However, existing linker units suffer from drawbacks such as insufficiently mild cleavage conditions, low cleavage efficiency, and excessively short read lengths when used for sequencing. Therefore, designing and synthesizing novel cleavable linker units and exploring suitable cleavage conditions are of great importance for improving sequencing efficiency and developing new sequencing methods. In this context, this invention develops a novel class of reversible termination nucleotides based on thiazolidinyl linker units. Under mild conditions, the linker units can be rapidly cleaved, the reaction is clean and thorough, and almost no side reactions are observed. Summary of the Invention
[0006] In view of the shortcomings of existing sequencing technologies, the purpose of this invention is to provide a novel reversible termination nucleotide and its application in DNA synthesis sequencing and single-molecule sequencing.
[0007] The objective of this invention is achieved through the following technical solution:
[0008] This invention provides a fluorescently labeled reversible nucleotide (a novel four-color fluorescently labeled reversible nucleotide sequencing reagent), the overall structural formula of which is shown below:
[0009] In this structural formula, Base consists of four different bases: U, C, A, and G; R is a chemical molecular group that links the thiazoline linker to the nucleotide; CleavableLinker is the thiazoline linker; R1 is a chemical molecular group that links the thiazoline linker to the fluorescein; and Dye is the fluorescent dye. Dye specifically includes Cy3, Cy5, Cy2, Cy3.5, TAMRA, FITC, sulfo-Cy3, sulfo-Cy2, sulfo-Cy5, and sulfo-Cy3.5.
[0010] This invention provides a novel fluorescently labeled reversible termination nucleotide, which can be classified into the following structures according to the type of linker unit:
[0011]
[0012] The present invention provides a novel reversible nucleotide DNA sequencing reagent (structural formula 1), wherein Base consists of four different bases: U, C, A, and G; R is a chemical molecular group that links the thiazoline linker unit to the nucleotide; R1 is a chemical molecular group that links the thiazoline linker unit to the fluorescein; and Dye is a fluorescent dye.
[0013] As one embodiment of the present invention, R is...
[0014] As one embodiment of the present invention, R1 is...
[0015] Preferably, the specific structure of structural formula 1 is as follows:
[0016]
[0017] This invention also provides a method for synthesizing nucleotides with reversible termination by thiazolidin; the method includes the following steps:
[0018] S1, glyoxylic acid and compounds The reaction yielded
[0019] S2, compound and compounds After the reaction, the trifluoroacetyl group was removed to obtain the compound.
[0020] S3, compound The fluorescently labeled reversible termination nucleotide is obtained by reacting with Sulf-Cy3-NHS, Cy3-NHS, Cy5-NHS, FITC-NHS or Cy3.5-NHS.
[0021] As one embodiment of the present invention, the compound (n = 1-10) are prepared by a method comprising the following steps: N-tert-butoxycarbonyl-S-triphenylmethyl-L-cysteine and a diamine compound undergo an amide condensation reaction to obtain the compound. The amino group is then protected by reacting with ethyl trifluoroacetate to give the compound. The compound was obtained by removing the Trt and Boc protecting groups using trifluoroacetic acid and triethylsilane.
[0022] As one embodiment of the present invention, the compound The compound was prepared by a method including the following steps: The compound was obtained by coupling with N-propynetrifluoroacetamide. It is then reacted with 2-chloro-1,3,2-benzodioxophosphazenecyclohexane-4-one and tri-n-butylamine pyrophosphate. The reactants are precipitated as solids, and concentrated ammonia is added to react them. After the solvent is evaporated, water is added to dissolve the solids, and the mixture is separated and purified to obtain the final product.
[0023] In one embodiment of the present invention, step S1 is carried out in the presence of ethanol and pyridine.
[0024] In one embodiment of the present invention, step S2 is carried out in the presence of N,N,N′,N′-tetramethyl-O-(N-succinimide)urea tetrafluoroborate and triethylamine.
[0025] The thiazolidinyl fluorescently labeled nucleotides provided by this invention, after participating in DNA chain elongation, can cause the linker unit to break rapidly under the action of the catalyst palladium, resulting in a clean and thorough reaction with almost no observed side reactions.
[0026] This invention also provides the application of this type of fluorescently labeled nucleotide in DNA synthesis sequencing and single-molecule sequencing.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] 1) The reversible termination nucleotide based on thiazolidinyl compounds of the present invention is novel and highly efficient, and there are no previous reports on it.
[0029] 2) The reversible termination nucleotide of the present invention, after participating in DNA strand elongation and breakage, leaves a group on the base. Smaller size is advantageous for DNA synthesis and sequencing.
[0030] 3) Through denaturing gel electrophoresis and mass spectrometry analysis of the extension and fragmentation products, the novel reversible termination nucleotide of this invention can rapidly cleave the ligation unit within 1 minute under the action of palladium ions in DNA synthesis sequencing and single-molecule sequencing. No oxidizing / reducing agent is required during cleavage, and the process is carried out under neutral conditions. These cleavage conditions are mild for DNA, with no significant damage to the DNA. The reaction is clean and thorough, with almost no observed side reactions. Attached Figure Description
[0031] Other features, objects, and advantages of the present invention will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings:
[0032] Figure 1 The overall structural formula of the fluorescently labeled nucleotides described in this invention is as follows;
[0033] Figure 2 The thiazolidinyl reversible termination nucleotide structure described in this invention is shown below.
[0034] Figure 3 The thiazolidinyl dUTP fluorescently labeled nucleotide and its synthesis method described in Example 1 of this invention;
[0035] Figure 4 The thiazolidinedioic acid dATP fluorescently labeled nucleotide and its synthesis method described in Example 2 of this invention;
[0036] Figure 5The thiazolidinyl dCTP fluorescently labeled nucleotide and its synthesis method described in Example 3 of this invention;
[0037] Figure 6 The thiazolidinedionyl dGTP fluorescently labeled nucleotide and its synthesis method described in Example 4 of this invention;
[0038] Figure 7 This is a route diagram showing the rapid and complete cleavage of the fluorescently labeled nucleotides described in this invention under the action of palladium.
[0039] Figure 8 This is an electrophoretic analysis diagram of the reaction products of the DNA strand extension reaction of the reversible termination nucleotide in the example; wherein, Lane 1: primer, Lane 2: 25-base primer as a reference, Lane 3: dUTP reversible termination nucleotide participating in the extension product of template 1, Lane 4: dUTP reversible termination nucleotide participating in the extension product of template 2, Lane 5: dUTP reversible termination nucleotide participating in the extension of template 3, Lane 6: dUTP reversible termination nucleotide participating in the extension of template 4, and Lane 7: dUTP reversible termination nucleotide participating in the extension of template 5.
[0040] Figure 9 The image shows the electrophoretic analysis of the reaction products of the reversible termination nucleotide cleavage reaction in the examples; where Lane 1: primer, Lane 2: 25-base primer as a control, Lane 3: dUTP reversible termination nucleotide participating in template 2 extension, Lane 4: cleavage product of dUTP reversible termination nucleotide extension product under palladium action, Lane 5: product of the above cleavage product further extension, and Lane 6: product of the above extension product further cleavage.
[0041] Figure 10 This is the MALDI-MS spectrum described in Example 1. Detailed Implementation
[0042] The present invention will now be described in detail with reference to specific embodiments. These embodiments will help those skilled in the art to further understand the present invention, but do not limit the invention in any way. It should be noted that those skilled in the art can make several changes and improvements without departing from the concept of the present invention. These all fall within the scope of protection of the present invention.
[0043] The overall structural formula of the fluorescently labeled nucleotides involved in this invention is as follows: Figure 1 As shown, the following examples are all thiazolidinyl reversibly terminated nucleotides, and their structural formulas are as follows: Figure 2 As shown.
[0044] Example 1: Synthetic route of fluorescently labeled nucleotide (Structural Formula I)
[0045] Synthetic routes such as Figure 3 As shown, it specifically includes:
[0046] Synthesis of Compound 1:
[0047]
[0048] The compound N-tert-butoxycarbonyl-S-triphenylmethyl-L-cysteine (11 mmol, 5.0 g) and N,N-carbonyldiimidazole (13 mmol, 2.1 g) were reacted in anhydrous N,N-dimethylformamide (50 mL) for 30 min, followed by the addition of anhydrous ethylenediamine (54 mmol, 3.2 g). The mixture was reacted at room temperature for 1 h, and the compound was obtained in 86% yield after purification by column chromatography.
[0049] Synthesis of compound 2:
[0050]
[0051] Compound 1 (5 mmol, 2.5 g), ethyl trifluoroacetate (10 mmol, 1.4 g), and triethylamine (15 mmol, 1.5 g) were reacted in methanol (100 mL) for 24 h. The compound was purified by column chromatography and given in 82% yield. 1 H NMR(700MHz,Chloroform-d)δ7.78(s,1H),7.41(d,J=7.8Hz,6H),7.30(t,J=7.8Hz,6H),7.23(t,J=7.3Hz,3H),6.43(s,1H),4.78( d,J=6.7Hz,1H),3.69(d,J=6.4Hz,1H),3.55-3.23(m,4H),2.72(dd,J=13.2,7.1Hz,1H),2.52(dd,J=13.1,5.3Hz,1H),1.40(s,9H). 13 C NMR(176MHz,Chloroform-d)δ172.50,157.69(q,J=37.2Hz),155.61,144.19,129.49,12 8.14,127.02,115.78(q,J=287.7Hz),80.81,67.41,53.86,40.59,38.68,33.34,28.18.
[0052] Synthesis of compound 3:
[0053]
[0054] Compound 2 (0.5 mmol, 300.0 mg) and triethylsilane (0.5 mmol, 58.1 mg) were reacted in a mixed solvent of trifluoroacetic acid (1 mL) and dichloromethane (2 mL) for 1 h under nitrogen protection. After removing the Boc and Trt protecting groups, the compound was purified by column chromatography in 64% yield.
[0055] Synthesis of compound 4:
[0056]
[0057] Under nitrogen protection, compound 3 (0.2 mmol, 51.9 mg) and glyoxylic acid (50% in H2O, 0.4 mmol, 29.6 mg) were dissolved in a mixed solvent of ethanol (1.5 mL) and pyridine (0.6 mL) and reacted for 3 h. After purification by column chromatography, the compound was given in 53% yield. 1 H NMR (700MHz, Methanol-d4) δ4.79 (s, 0.47H), 4.71 (s, 0.52H), 4.40 (dd, J = 6.7, 2.6Hz, 0.53H), 3.79 (dd, J=8.5, 6.1Hz, 0.46H), 3.56-3.33 (m, 4H), 3.10 (m, 1H), 2.89 (m, 1H). 13 C NMR(176MHz,Methanol-d4)δ176.27,176.06,173.24,172.16,158.61-157.29(m),120. 48-112.16(m),67.80,67.40,67.20,67.06,39.11,38.93,37.90,37.85,36.91,34.51.
[0058] Synthesis of compound 5:
[0059]
[0060] Trifluoroacetylpropynylamine (3 mmol, 0.45 g) and iodide (2 mmol, 0.71 g) were reacted in anhydrous N,N-dimethylformamide (14 mL) under nitrogen protection for 24 h in the presence of copper iodide (0.2 mmol, 38 mg), tetrakis(triphenylphosphine)palladium (0.04 mmol, 46 mg) and triethylamine (1.6 mL). The compound was purified by column chromatography in 61% yield.
[0061] Synthesis of compound 6:
[0062]
[0063] Tri-n-butylamine pyrophosphate (0.75 mmol, 411 mg) was dissolved in a mixed solvent of anhydrous N,N-dimethylformamide (1 mL) and tri-n-butylamine (1 mL). 2-chloro-4H-1,3,2-benzodioxophosphoro-4-one (0.5 mmol, 101 mg) dissolved in anhydrous N,N-dimethylformamide (1 mL) was added to the solution, and the mixture was stirred for 30 min. After the reaction, compound 5 (0.5 mmol, 188 mg) dissolved in anhydrous N,N-dimethylformamide (3 mL) was added to the solution. After reacting for 3 h, 3% iodine solution (pyridine / water = 9 / 1) was added, and the mixture reacted for 15 min to obtain a brown color that did not fade. Water (10 mL) was then added, and the reaction continued for 3 h. A suitable amount of saturated sodium chloride and ethanol were added to precipitate the crude product. The crude product was dissolved in concentrated ammonia (5 mL) and reacted for 6 h to remove the trifluoroacetyl group. The compound was obtained in 45% yield by preparative HPLC separation. 1 H NMR(700MHz, Deuterium Oxide)δ8.33(s,1H),6.14(t,J=6.0Hz,1H),4.52(q,J=5.4Hz,1H),4.20-4.09(m,2H),4.04(s,1H),3.86(d,J=2.9Hz,2H),2.34-2.21(m,2H). 31 P NMR (283MHz, Deuterium Oxide) δ -7.03 (d, J = 20.2Hz), -11.43 (d, J = 19.0Hz), -22.05 (t, J = 19.1Hz).
[0064] Synthesis of compound 7:
[0065]
[0066] Compound 4 (0.1 mmol, 31.5 mg) was activated for 30 min in N,N,N,N′-tetramethyl-O-(N-succinimide)urea tetrafluoroborate (0.12 mmol, 36.1 mg), triethylamine (0.3 mmol, 30.4 mg), and N,N-dimethylformamide (1.5 mL). Then, an aminoated dNTP compound 6 (0.1 mmol, 52.1 mg) dissolved in sodium bicarbonate-sodium carbonate buffer (1.5 mL) was added, and the mixture was reacted for 3 h. The product was dissolved in ammonia (2 mL) and reacted for 3 h to remove the trifluoroacetyl group. The compound was then separated by preparative HPLC in 42% yield. MALDI-MS: calc. for C 19 H 30 N6O 16 P3S + [M] +723.0646, found 723.0683.
[0067] Synthesis of compound 8:
[0068]
[0069] Fluorescent dye Cy3 (0.016 mmol, 10 mg) was dissolved in triethylamine (0.016 mmol, 1.6 mg) and anhydrous N,N-dimethylformamide (1 mL). Compound 7 (0.008 mmol, 5.8 mg) dissolved in sodium bicarbonate-sodium carbonate buffer (2 mL) was added. The mixture was reacted for 3 h, and the reversible termination nucleotide was obtained in 55% yield by preparative HPLC separation. Figure 10 MALDI-MS:calc.for C 49 H 64 N8O 17 P3S + [M] + 1161.3317, found 1161.3299.
[0070] Example 2: Synthetic route of fluorescently labeled nucleotide (Structure II)
[0071] Synthetic routes such as Figure 4 As shown, it specifically includes:
[0072] Synthesis of Compound 1:
[0073]
[0074] The compound N-tert-butoxycarbonyl-S-triphenylmethyl-L-cysteine (11 mmol, 5.0 g) and N,N-carbonyldiimidazole (13 mmol, 2.1 g) were reacted in anhydrous N,N-dimethylformamide (50 mL) for 30 min, followed by the addition of anhydrous ethylenediamine (54 mmol, 3.2 g). The mixture was reacted at room temperature for 1 h, and the compound was obtained in 86% yield after purification by column chromatography.
[0075] Synthesis of compound 2:
[0076]
[0077] Compound 1 (5 mmol, 2.5 g), ethyl trifluoroacetate (10 mmol, 1.4 g), and triethylamine (15 mmol, 1.5 g) were reacted in methanol (100 mL) for 24 h. The compound was purified by column chromatography and given in 82% yield. 1H NMR(700MHz,Chloroform-d)δ7.78(s,1H),7.41(d,J=7.8Hz,6H),7.30(t,J=7.8Hz,6H),7.23(t,J=7.3Hz,3H),6.43(s,1H),4.78( d,J=6.7Hz,1H),3.69(d,J=6.4Hz,1H),3.55-3.23(m,4H),2.72(dd,J=13.2,7.1Hz,1H),2.52(dd,J=13.1,5.3Hz,1H),1.40(s,9H). 13 C NMR(176MHz,Chloroform-d)δ172.50,157.69(q,J=37.2Hz),155.61,144.19,129.49,12 8.14,127.02,115.78(q,J=287.7Hz),80.81,67.41,53.86,40.59,38.68,33.34,28.18.
[0078] Synthesis of compound 3:
[0079]
[0080] Compound 2 (0.5 mmol, 300.0 mg) and triethylsilane (0.5 mmol, 58.1 mg) were reacted in a mixed solvent of trifluoroacetic acid (1 mL) and dichloromethane (2 mL) for 1 h under nitrogen protection. After removing the Boc and Trt protecting groups, the compound was purified by column chromatography in 64% yield.
[0081] Synthesis of compound 4:
[0082]
[0083] Under nitrogen protection, compound 3 (0.2 mmol, 51.9 mg) and glyoxylic acid (50% in H2O, 0.4 mmol, 29.6 mg) were dissolved in a mixed solvent of ethanol (1.5 mL) and pyridine (0.6 mL) and reacted for 3 h. After purification by column chromatography, the compound was given in 53% yield. 1 H NMR (700MHz, Methanol-d4) δ4.79 (s, 0.47H), 4.71 (s, 0.52H), 4.40 (dd, J = 6.7, 2.6Hz, 0.53H), 3.79 (dd, J=8.5, 6.1Hz, 0.46H), 3.56-3.33 (m, 4H), 3.10 (m, 1H), 2.89 (m, 1H). 13C NMR(176MHz,Methanol-d4)δ176.27,176.06,173.24,172.16,158.61-157.29(m),120. 48-112.16(m),67.80,67.40,67.20,67.06,39.11,38.93,37.90,37.85,36.91,34.51.
[0084] Synthesis of compound 9:
[0085]
[0086] Trifluoroacetylpropynylamine (3 mmol, 0.45 g) and iodide (2 mmol, 0.75 g) were reacted in anhydrous N,N-dimethylformamide (14 mL) under nitrogen protection for 24 h in the presence of copper iodide (0.2 mmol, 38 mg), tetrakis(triphenylphosphine)palladium (0.04 mmol, 46 mg) and triethylamine (1.6 mL). The compound was purified by column chromatography in 67% yield.
[0087] Synthesis of compound 10:
[0088]
[0089] Tri-n-butylamine pyrophosphate (0.75 mmol, 411 mg) was dissolved in a mixed solvent of anhydrous N,N-dimethylformamide (1 mL) and tri-n-butylamine (1 mL). 2-chloro-4H-1,3,2-benzodioxophosphoro-4-one (0.5 mmol, 101 mg) dissolved in anhydrous N,N-dimethylformamide (1 mL) was added to the solution, and the mixture was stirred for 30 min. After the reaction, compound 9 (0.5 mmol, 199 mg) dissolved in anhydrous N,N-dimethylformamide (3 mL) was added to the solution. After reacting for 3 h, 3% iodine solution (pyridine / water = 9 / 1) was added, and the mixture was reacted for 15 min to remove the brown color. Water (10 mL) was then added, and the reaction was continued for 3 h. A suitable amount of saturated sodium chloride and ethanol were added to precipitate the crude product. The crude product was dissolved in concentrated ammonia (5 mL) and reacted for 6 h to remove the trifluoroacetyl group. The compound was separated by preparative HPLC in 41% yield. MALDI-MS: calc. for C 14 H 21 N5O 12 P3 + [M] + 544.0394, found 544.0389.
[0090] Synthesis of compound 11:
[0091]
[0092] Compound 4 (0.1 mmol, 31.5 mg) was activated for 30 min in N,N,N′,N′-tetramethyl-O-(N-succinimide)urea tetrafluoroborate (0.12 mmol, 36.1 mg), triethylamine (0.3 mmol, 30.4 mg), and N,N-dimethylformamide (1.5 mL). Then, dATP compound 10 (0.1 mmol, 54.0 mg) dissolved in sodium bicarbonate-sodium carbonate buffer (1.5 mL) was added, and the mixture was reacted for 3 h. The product was dissolved in ammonia (2 mL) and reacted for 3 h to remove the trifluoroacetyl group. The compound was then separated by preparative HPLC in 47% yield. MALDI-MS: calc. for C 21 H 32 N8O 14 P3S + [M] + 745.0966, found 745.0923.
[0093] Synthesis of compound 12:
[0094]
[0095] Fluorescent dye CY5 (0.016 mmol, 9.3 mg) was dissolved in triethylamine (0.016 mmol, 1.6 mg) and anhydrous N,N-dimethylformamide (1 mL). Compound 11 (0.008 mmol, 6.0 mg) dissolved in sodium bicarbonate-sodium carbonate buffer (2 mL) was added. The mixture was reacted for 3 h, and the reversible termination nucleotide was obtained in 57% yield by preparative HPLC. MALDI-MS: calc. for C 53 H 68 N 10 O 15 P3S + [M] + 1209.3794, found 1209.3761.
[0096] Example 3: Synthetic route of fluorescently labeled nucleotide (Structure III)
[0097] Synthetic routes such as Figure 5 As shown, it specifically includes:
[0098] Synthesis of Compound 1:
[0099]
[0100] The compound N-tert-butoxycarbonyl-S-triphenylmethyl-L-cysteine (11 mmol, 5.0 g) and N,N-carbonyldiimidazole (13 mmol, 2.1 g) were reacted in anhydrous N,N-dimethylformamide (50 mL) for 30 min, followed by the addition of anhydrous ethylenediamine (54 mmol, 3.2 g). The mixture was reacted at room temperature for 1 h, and the compound was obtained in 86% yield after purification by column chromatography.
[0101] Synthesis of compound 2:
[0102]
[0103] Compound 1 (5 mmol, 2.5 g), ethyl trifluoroacetate (10 mmol, 1.4 g), and triethylamine (15 mmol, 1.5 g) were reacted in methanol (100 mL) for 24 h. The compound was purified by column chromatography and given in 82% yield. 1 H NMR(700MHz,Chloroform-d)δ7.78(s,1H),7.41(d,J=7.8Hz,6H),7.30(t,J=7.8Hz,6H),7.23(t,J=7.3Hz,3H),6.43(s,1H),4.78( d,J=6.7Hz,1H),3.69(d,J=6.4Hz,1H),3.55-3.23(m,4H),2.72(dd,J=13.2,7.1Hz,1H),2.52(dd,J=13.1,5.3Hz,1H),1.40(s,9H). 13 C NMR(176MHz,Chloroform-d)δ172.50,157.69(q,J=37.2Hz),155.61,144.19,129.49,12 8.14,127.02,115.78(q,J=287.7Hz),80.81,67.41,53.86,40.59,38.68,33.34,28.18.
[0104] Synthesis of compound 3:
[0105]
[0106] Compound 2 (0.5 mmol, 300.0 mg) and triethylsilane (0.5 mmol, 58.1 mg) were reacted in a mixed solvent of trifluoroacetic acid (1 mL) and dichloromethane (2 mL) for 1 h under nitrogen protection. After removing the Boc and Trt protecting groups, the compound was purified by column chromatography in 64% yield.
[0107] Synthesis of compound 4:
[0108]
[0109] Under nitrogen protection, compound 3 (0.2 mmol, 51.9 mg) and glyoxylic acid (50% in H2O, 0.4 mmol, 29.6 mg) were dissolved in a mixed solvent of ethanol (1.5 mL) and pyridine (0.6 mL) and reacted for 3 h. After purification by column chromatography, the compound was given in 53% yield. 1 H NMR (700MHz, Methanol-d4) δ4.79 (s, 0.47H), 4.71 (s, 0.52H), 4.40 (dd, J = 6.7, 2.6Hz, 0.53H), 3.79 (dd, J=8.5, 6.1Hz, 0.46H), 3.56-3.33 (m, 4H), 3.10 (m, 1H), 2.89 (m, 1H). 13 C NMR(176MHz,Methanol-d4)δ176.27,176.06,173.24,172.16,158.61-157.29(m),120. 48-112.16(m),67.80,67.40,67.20,67.06,39.11,38.93,37.90,37.85,36.91,34.51.
[0110] Synthesis of compound 13:
[0111]
[0112] Trifluoroacetylpropynylamine (3 mmol, 0.45 g) and iodide (2 mmol, 0.70 g) were reacted in anhydrous N,N-dimethylformamide (14 mL) under nitrogen protection for 24 h in the presence of copper iodide (0.2 mmol, 38 mg), tetrakis(triphenylphosphine)palladium (0.04 mmol, 46 mg) and triethylamine (1.6 mL). The compound was purified by column chromatography in 57% yield.
[0113] Synthesis of compound 14:
[0114]
[0115] Tri-n-butylamine pyrophosphate (0.75 mmol, 411 mg) was dissolved in a mixed solvent of anhydrous N,N-dimethylformamide (1 mL) and tri-n-butylamine (1 mL). 2-chloro-4H-1,3,2-benzodioxophosphoro-4-one (0.5 mmol, 101 mg) dissolved in anhydrous N,N-dimethylformamide (1 mL) was added to the solution, and the mixture was stirred for 30 min. After the reaction, compound 13 (0.5 mmol, 188 mg) dissolved in anhydrous N,N-dimethylformamide (3 mL) was added to the solution. After reacting for 3 h, 3% iodine solution (pyridine / water = 9 / 1) was added, and the mixture reacted for 15 min to obtain a brown color that did not fade. Water (10 mL) was then added, and the reaction continued for 3 h. A suitable amount of saturated sodium chloride and ethanol were added to precipitate the crude product. The crude product was dissolved in concentrated ammonia (5 mL) and reacted for 6 h to remove the trifluoroacetyl group. The compound was separated by preparative HPLC in 49% yield. MALDI-MS: calc. for C 12 H 20 N4O 13 P3 + [M] + 521.0234, found 521.0256.
[0116] Synthesis of compound 15:
[0117]
[0118] Compound 4 (0.1 mmol, 31.5 mg) was activated for 30 min in N,N,N′,N′-tetramethyl-O-(N-succinimide)urea tetrafluoroborate (0.12 mmol, 36.1 mg), triethylamine (0.3 mmol, 30.4 mg), and N,N-dimethylformamide (1.5 mL). Then, 0.1 mmol, 52.0 mg of amination-modified dCTP compound 14, dissolved in sodium bicarbonate-sodium carbonate buffer (1.5 mL), was added, and the mixture was reacted for 3 h. The product was dissolved in ammonia (2 mL) and reacted for 3 h to remove the trifluoroacetyl group. The compound was then separated by preparative HPLC in 43% yield. MALDI-MS: calc. for C 19 H 31 N7O 15 P3S + [M] + 722.0806, found 722.0863.
[0119] Synthesis of compound 16:
[0120]
[0121] The fluorescent dye FITC (0.016 mmol, 9.7 mg) was dissolved in triethylamine (0.016 mmol, 1.6 mg) and anhydrous N,N-dimethylformamide (1 mL). Compound 15 (0.008 mmol, 5.8 mg) dissolved in sodium bicarbonate-sodium carbonate buffer (2 mL) was added. The mixture was reacted for 3 h, and the reversible termination nucleotide was obtained in 59% yield by preparative HPLC. MALDI-MS: calc. for C 45 H 51 N9O 21 P3S2 + [M] + 1210.1848, found 1210.1841.
[0122] Example 4: Synthetic route of fluorescently labeled nucleotide (structure IV)
[0123] Synthetic routes such as Figure 6 As shown, it specifically includes:
[0124] Synthesis of Compound 1:
[0125]
[0126] The compound N-tert-butoxycarbonyl-S-triphenylmethyl-L-cysteine (11 mmol, 5.0 g) and N,N-carbonyldiimidazole (13 mmol, 2.1 g) were reacted in anhydrous N,N-dimethylformamide (50 mL) for 30 min, followed by the addition of anhydrous ethylenediamine (54 mmol, 3.2 g). The mixture was reacted at room temperature for 1 h, and the compound was obtained in 86% yield after purification by column chromatography.
[0127] Synthesis of compound 2:
[0128]
[0129] Compound 1 (5 mmol, 2.5 g), ethyl trifluoroacetate (10 mmol, 1.4 g), and triethylamine (15 mmol, 1.5 g) were reacted in methanol (100 mL) for 24 h. The compound was purified by column chromatography and given in 82% yield. 1H NMR(700MHz,Chloroform-d)δ7.78(s,1H),7.41(d,J=7.8Hz,6H),7.30(t,J=7.8Hz,6H),7.23(t,J=7.3Hz,3H),6.43(s,1H),4.78( d,J=6.7Hz,1H),3.69(d,J=6.4Hz,1H),3.55-3.23(m,4H),2.72(dd,J=13.2,7.1Hz,1H),2.52(dd,J=13.1,5.3Hz,1H),1.40(s,9H). 13 C NMR(176MHz,Chloroform-d)δ172.50,157.69(q,J=37.2Hz),155.61,144.19,129.49,12 8.14,127.02,115.78(q,J=287.7Hz),80.81,67.41,53.86,40.59,38.68,33.34,28.18.
[0130] Synthesis of compound 3:
[0131]
[0132] Compound 2 (0.5 mmol, 300.0 mg) and triethylsilane (0.5 mmol, 58.1 mg) were reacted in a mixed solvent of trifluoroacetic acid (1 mL) and dichloromethane (2 mL) for 1 h under nitrogen protection. After removing the Boc and Trt protecting groups, the compound was purified by column chromatography in 64% yield.
[0133] Synthesis of compound 4:
[0134]
[0135] Under nitrogen protection, compound 3 (0.2 mmol, 51.9 mg) and glyoxylic acid (50% in H2O, 0.4 mmol, 29.6 mg) were dissolved in a mixed solvent of ethanol (1.5 mL) and pyridine (0.6 mL) and reacted for 3 h. After purification by column chromatography, the compound was given in 53% yield. 1 H NMR (700MHz, Methanol-d4) δ4.79 (s, 0.47H), 4.71 (s, 0.52H), 4.40 (dd, J = 6.7, 2.6Hz, 0.53H), 3.79 (dd, J=8.5, 6.1Hz, 0.46H), 3.56-3.33 (m, 4H), 3.10 (m, 1H), 2.89 (m, 1H). 13C NMR(176MHz,Methanol-d4)δ176.27,176.06,173.24,172.16,158.61-157.29(m),120. 48-112.16(m),67.80,67.40,67.20,67.06,39.11,38.93,37.90,37.85,36.91,34.51.
[0136] Synthesis of compound 17:
[0137]
[0138] Trifluoroacetylpropynylamine (3 mmol, 0.45 g) and iodide (2 mmol, 0.78 g) were reacted in anhydrous N,N-dimethylformamide (14 mL) under nitrogen protection for 24 h in the presence of copper iodide (0.2 mmol, 38 mg), tetrakis(triphenylphosphine)palladium (0.04 mmol, 46 mg) and triethylamine (1.6 mL). The compound was purified by column chromatography in 52% yield.
[0139] Synthesis of compound 18:
[0140]
[0141] Tri-n-butylamine pyrophosphate (0.75 mmol, 411 mg) was dissolved in a mixed solvent of anhydrous N,N-dimethylformamide (1 mL) and tri-n-butylamine (1 mL). 2-chloro-4H-1,3,2-benzodioxophosphoro-4-one (0.5 mmol, 101 mg) dissolved in anhydrous N,N-dimethylformamide (1 mL) was added to the solution, and the mixture was stirred for 30 min. After the reaction, compound 17 (0.5 mmol, 208 mg) dissolved in anhydrous N,N-dimethylformamide (3 mL) was added to the solution. After reacting for 3 h, 3% iodine solution (pyridine / water = 9 / 1) was added, and the mixture reacted for 15 min to remove the brown color without fading. Water (10 mL) was then added, and the reaction continued for 3 h. A suitable amount of saturated sodium chloride and ethanol were added to precipitate the crude product. The crude product was dissolved in concentrated ammonia (5 mL) and reacted for 6 h to remove the trifluoroacetyl group. The compound was separated by preparative HPLC in 43% yield. MALDI-MS: calc. for C 14 H 21 N5O 13 P3 + [M] + 560.0343, found 560.0380.
[0142] Synthesis of compound 19:
[0143]
[0144] Compound 4 (0.1 mmol, 31.5 mg) was activated for 30 min in N,N,N′,N′-tetramethyl-O-(N-succinimide)urea tetrafluoroborate (0.12 mmol, 36.1 mg), triethylamine (0.3 mmol, 30.4 mg), and N,N-dimethylformamide (1.5 mL). Then, 0.1 mmol, 56.0 mg of amination-modified dGTP compound 18 dissolved in sodium bicarbonate-sodium carbonate buffer (1.5 mL) was added, and the mixture was reacted for 3 h. The product was dissolved in ammonia (2 mL) and reacted for 3 h to remove the trifluoroacetyl group. The compound was then separated by preparative HPLC in 49% yield. MALDI-MS: calc. for C 21 H 32 N8O 15 P3S + [M] + 761.0915, found 761.0982.
[0145] Synthesis of compound 20:
[0146]
[0147] Fluorescent dye CY3.5 (0.016 mmol, 10.5 mg) was dissolved in triethylamine (0.016 mmol, 1.6 mg) and anhydrous N,N-dimethylformamide (1 mL). Compound 19 (0.008 mmol, 6.0 mg) dissolved in sodium bicarbonate-sodium carbonate buffer (2 mL) was added. The mixture was reacted for 3 h, and the reversible termination nucleotide was obtained in 51% yield by preparative HPLC. MALDI-MS: calc. for C 59 H 70 N 10 O 16 P3S + [M] + 1299.3899, found 1299.3857.
[0148] Example 5: Rapid and complete cleavage of four-color fluorescently labeled nucleotides under palladium catalysis
[0149] Fracture test route as follows Figure 7 As shown. The four-color fluorescently labeled nucleotides (Formulas I-IV) prepared in Examples 1-4 can be rapidly cleaved within 1 minute under the action of palladium ions. Cleavage does not require the participation of an oxidizing / reducing agent and is carried out under neutral conditions. The products after the reaction ( 1 Characterization by 1H-NMR and 1H-MS showed that the fracture efficiency was 100%. PAGE analysis of the denatured gel confirmed this. Figure 9 The breakage conditions are mild for DNA, causing no significant damage to the DNA, resulting in a clean and complete breakage without the formation of byproducts.
[0150] Example 6: DNA strand elongation reaction with reversible terminator
[0151] The reversible termination nucleotides I-IV synthesized in Examples 1-4 were confirmed by sequencing gel to successfully participate in DNA strand elongation and breakage, demonstrating their potential for DNA sequencing and meeting the requirements of DNA synthesis sequencing.
[0152] (1) DNA strand annealing and extension
[0153] Take template and primer in a 1:1 molar ratio as shown in Table 1, mix well, keep at 95℃ for 3 min, and then slowly cool to room temperature at a rate of 0.1℃ / min to obtain double-stranded DNA (dsDNA); prepare a 20 μL extension reaction solution system according to the components listed in Table 2, mix the prepared reaction solution well, and perform the chain extension reaction on a PCR instrument (Bio-rad T100, US) under the following conditions: 65℃ for 5 min → keep at 16℃.
[0154] (2) Fracture
[0155] After DNA strand extension, the DNA was precipitated with ethanol, and 10 μL of 50 μM allyl palladium(II) chloride was added. The mixture was then treated at 37 °C for 1 min. The reaction product was used for subsequent reversible termination nucleotide extension reactions.
[0156] (3) Gel electrophoresis detection
[0157] The extended and fragmented samples were analyzed by gel electrophoresis using 12% denaturing polyacrylamide containing 7M urea. Before electrophoresis, the prepared gel was run at a constant voltage of 2000V and a constant power of 40W for 30 min. 1 μL of sample (approximately 15 ng / μL DNA) was mixed with 2 μL of loading buffer containing labeled dye, and then electrophoresis was performed at a constant voltage of 2000V and a constant power of 40W for 3 h. The gel was then observed under 785 nm laser excitation using an Odyssey infrared imaging system (LI-COR Biosciences, US). Figure 8 , Figure 9 Experimental results show that the reversible termination nucleotide can achieve 100% extension in the sequencing cycle, and the extended product can be 100% cleaved. After the first extension product is cleaved, the second extension can still achieve 100% extension and 100% cleavage. Furthermore, when there are multiple consecutive identical bases in the template, the reversible termination nucleotide we synthesized only extends one base per sequencing cycle.
[0158] Table 1 DNA Synthesis Sequencing Templates and Primers
[0159]
[0160] Table 2 Buffer systems for DNA synthesis and sequencing
[0161]
[0162] Example 7: Four-color fluorescently labeled reversible termination nucleotide DNA single-molecule sequencing system
[0163] This embodiment provides a DNA single-molecule sequencing system and sequencing method. In this embodiment, the reversible termination nucleotides I-IV prepared in Examples 1-4 are selected as four-color fluorescent reversible termination nucleotide sequencing reagents.
[0164]
[0165]
[0166] The four different template sequences to be tested are as follows:
[0167] 5'-CTACGTTCGAACTACTAACTTGATGTAGCTTCGTAGTAATTTTTTTTTTTTTT TTTTTT-3' (sequence 1),
[0168] 5'-CTACGTTCGAACTACTAATGGCCAACTTTAGGTACAGGCTTTTTTTTTTTTTTTTTTTTT-3' (sequence 2),
[0169] 5'-CTACGTTCGAACTACTAAGCAATCCGGCAGATCGTCACTTTTTTTTTTTTTTT TTTTTT-3' (sequence 3),
[0170] 5'-CTACGTTCGAACTACTAAAACTGGTACAGCCAACGTCTGTTTTTTTTTTTTTTTTTTTT-3' (sequence 4).
[0171] First, the templates with the four different sequences were hybridized with primers fixed on the surface of the flow cell reactor at 65°C for 5 min. Then, under the action of DNA polymerase, four different fluorescently labeled reversible termination nucleotide primers were used for extension reaction for 15 min at 60°C. After the first extension reaction, the information of the target bases could be obtained by detecting the fluorescence signal of the extension product. Then, the fluorescein labeled on the bases was removed under the action of palladium. Using the fluorescence image after the first extension as the localization fluorescence, the same steps were used for the second extension cycle, and so on, for multiple sequencing cycles. In this embodiment, the fluorescence information of the previous extension product is used as the localization information of the next extension product, and it is not necessary to label the 3' end of the target template with specific localization fluorescence information. Furthermore, in our preliminary experiments, we found that the four-color fluorescence single-molecule sequencing system does not require special labeling of localization information on the target template, and therefore there is no fluorescence quenching due to localization information. Therefore, the single-molecule sequencing system described in this invention can achieve long read lengths and low error rates, resulting in high-throughput single-molecule sequencing.
[0172] In summary, the thiazolidinyl tetrachromatographically labeled nucleotides described in this invention offer advantages such as long read lengths and low error rates for both DNA synthesis sequencing and single-molecule sequencing. Furthermore, they boast high sequencing efficiency, requiring only one sequencing cycle to determine the read length of a single base. In contrast, existing monochrome single-molecule sequencing systems require four sequencing cycles to determine the read length of a single base, thus improving sequencing efficiency by four times.
[0173] It should be noted that the four-color fluorescent single-molecule sequencing system provided by this invention is not limited to the currently proposed types of reversible terminators, but is also applicable to other types of reversible terminators.
[0174] This invention has many specific applications, and the above description is only a preferred embodiment. It should be noted that the above embodiments are for illustrative purposes only and are not intended to limit the scope of protection of this invention. For those skilled in the art, several improvements can be made without departing from the principle of this invention, and these improvements should also be considered within the scope of protection of this invention.
Claims
1. A fluorescently labeled reversible termination nucleotide having the structure of: ,n=1-10; ,n=1-10; ,n=1-10; 2. Use of the fluorescently labeled reversible termination nucleotide of claim 1 in non-diagnostic DNA synthesis sequencing or single molecule sequencing. ,n=1-10。
Citation Information
Patent Citations
Four-color fluorescence labeling reversible terminal and use thereof in DNA (Deoxyribonucleic Acid) sequencing
CN103484106A
Fluorescence labelled nucleotide based on molecular glue and use thereof in DNA sequencing
CN104693258A
